Gland Pharma through its partner has launched Bortezomib for Injection 35 mgvial Single-Dose Vial in the US Market It is the bioequivalent and therapeutically equivalent to thereference listed drug RLD Velcade for Injection 35 mgvial of Takeda Pharmaceuticals USA Inc Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma Velcade has a market size of USD 1172 million for the twelve months ending March 2022 according to IQVIA Gland Pharmas partner has received the ANDA approval for the product from US Food Drug Administration US FDA Gland Pharma is manufacturing and supplying this product to its partner for the US market
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
